Ferric carboxymaltose for anemia in late pregnancy: a randomized controlled trial
Top Cited Papers
Open Access
- 6 January 2025
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 31 (1) , 197-206
Abstract
Over 46% of African pregnant women are anemic. Oral iron is recommended but often suboptimal, particularly late in pregnancy. Intravenous ferric carboxymaltose (FCM) could treat anemia in women in the third trimester in sub-Saharan Africa. In an open-label, individually randomized trial in antenatal clinics in southern Malawi, we randomized 590 women at 27–35 weeks of gestation with capillary hemoglobin −1 to FCM (20 mg kg−1 up to 1,000 mg, once at enrollment) or standard of care (60 mg elemental iron, twice daily for 90 days). Participants and their infants were followed to 4 weeks postpartum. Primary outcomes were maternal anemia at 36 weeks’ gestation or delivery (whichever occurred first) and neonatal birthweight. At the primary timepoint, 126 of 270 (46.7%) of women in the FCM group were anemic, compared to 170 of 271 (67.3%) women in the standard-of-care group (PR, 0.74 (95% CI 0.64, 0.87); P = 0.0002). There was no difference between groups in birthweight (mean difference 10.9 g (−65.7, 87.5 g); P = 0.78). No serious infusion-related reactions occurred, and there were no differences in adverse events between groups. In Malawian women in late pregnancy, FCM effectively and safely reduced anemia before childbirth. Australia New Zealand Clinical Trial registration: ANZCTR12621001239853Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-010612)
- Department of Health | National Health and Medical Research Council (GNT2009047)
This publication has 30 references indexed in Scilit:
- Iron homeostasis during pregnancyThe American Journal of Clinical Nutrition, 2017
- Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trialsThe Lancet Haematology, 2017
- The available intravenous iron formulations: History, efficacy, and toxicologyHemodialysis International, 2017
- How I treat anemia in pregnancy: iron, cobalamin, and folateBlood, 2017
- Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP)Journal of Perinatal Medicine, 2016
- Effect of Daily Antenatal Iron Supplementation onPlasmodiumInfection in Kenyan WomenJAMA, 2015
- Daily oral iron supplementation during pregnancyCochrane Database of Systematic Reviews, 2015
- Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling studyThe Lancet Global Health, 2014
- Hypersensitivity from Intravenous Iron ProductsImmunology and Allergy Clinics of North America, 2014
- Adaptive increase in sample size when interim results are promising: A practical guide with examplesStatistics in Medicine, 2010